Zydus Lifesciences Limited has informed the Exchange about press release dated 07-Nov-2022 titled Zydus receives EIR with Voluntary Action Indicated (VAI) from USFDA for its Moraiya manufacturing facility
Press Release Nov 07 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report from the USFDA for its Moraiya manufacturing facility. The report indicates that the facility's inspection classification is Voluntary Action Indicated, following an inspection conducted earlier in the year. The company is committed to providing quality healthcare solutions and aims to transform lives through innovative discoveries.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 03 2022
- Press Release Oct 29 2022
- Press Release Oct 26 2022
- Press Release Oct 22 2022
- Press Release Oct 17 2022
Later from Zydus Lifesciences
- Press Release Nov 08 2022
- Press Release Nov 16 2022
- Press Release Nov 23 2022
- Press Release Nov 28 2022
- Press Release Dec 01 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences